EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Dual Antiplatelet Therapy and Very Early Neurological Deterioration after Non-Cardioembolic Stroke According to Stroke Etiology

Rosa Sruthy Pereppadan, Sabrina Schärli, Shania Brülisauer, Francesco Valletta, Dimitrios Vlachos, Thomas R Schneider, Victoria Hellstern, Gian Marco De Marchis, Tolga D Dittrich

Cerebrovascular Diseases Extra · 2026

DOI: 10.1159/000552952 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Cerebrovascular Diseases Extra, 2026. Verfasst von Rosa Sruthy Pereppadan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Stroke Center, University Teaching and Research Hospital, Health Eastern Switzerland (HOCH), Cantonal Hospital St. Gallen…. Hauptthemen laut MEDLINE: Platelet Aggregation Inhibitors, Dual Anti-Platelet Therapy, Ischemic Stroke, Intracranial Arteriosclerosis. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Early neurological deterioration after ischemic stroke is associated with worse clinical outcome, yet little is known about the frequency and determinants of neurological worsening during the first 24 h after admission. Dual antiplatelet therapy (DAPT) is recommended early after minor non-cardioembolic stroke to reduce recurrent ischemic events, but its relationship with very early deterioration (vEND) and potential differences across stroke etiologies remain unclear.

Methods

We conducted a retrospective single-center cohort study including consecutive adults with non-cardioembolic ischemic stroke admitted to a Swiss tertiary stroke center between 2014 and 2023. vEND was defined as neurological worsening within 24 h using 2 thresholds (NIHSS increase ≥4 points [primary] and ≥2 points [secondary]). Patients were categorized according to antiplatelet strategy (newly initiated DAPT vs. single antiplatelet therapy [SAPT]) and stroke etiology (large artery atherosclerosis [LAA] vs. non-LAA). Associations between antiplatelet therapy and vEND were analyzed using propensity score-weighted logistic regression with stabilized inverse probability of treatment weights and doubly robust adjustment. Adjusted predicted probabilities and risk differences were estimated using marginal standardization.

Results

Among 1,207 patients with non-cardioembolic stroke, vEND occurred in 22.2% using the primary definition (NIHSS increase ≥4 points) and in 25.8% using the secondary definition (NIHSS increase ≥2 points). vEND was more frequent in non-LAA than LAA stroke under both definitions (23.5% vs. 17.6% and 26.4% vs. 23.7%, respectively). Patients with LAA were more likely to receive DAPT than those without LAA (33.6% vs. 14.4%, p < 0.001). After weighting and adjustment, the association between antiplatelet therapy and vEND differed by stroke etiology (pinteraction

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Platelet Aggregation InhibitorsDual Anti-Platelet TherapyIschemic StrokeIntracranial ArteriosclerosisHumansRetrospective StudiesAgedMaleFemaleRisk FactorsTime FactorsTreatment OutcomeRisk AssessmentMiddle AgedAged, 80 and overDisability EvaluationSwitzerlandDisease Progression

Stichwörter der Autor:innen

Antiplatelet therapyEarly neurological deteriorationIschemic stroke

Substanzen

Platelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Department of Neurology and Stroke Center, University Teaching and Research Hospital, Health Eastern Switzerland (HOCH), Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
  • DAI di Neuroscienze, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.
  • Department of Radiology and Nuclear Medicine, University Teaching and Research Hospital, Health Eastern Switzerland (HOCH), Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
  • Department of Clinical Research, University of Basel, Basel, Switzerland.
  • Department of Neurology and Stroke Center, University Teaching and Research Hospital, Health Eastern Switzerland (HOCH), Cantonal Hospital St. Gallen, St. Gallen, Switzerland, tolga.dittrich@h-och.ch.
  • Department of Clinical Research, University of Basel, Basel, Switzerland, tolga.dittrich@h-och.ch.

Zitieren

APA

Pereppadan, R. S., Schärli, S., Brülisauer, S., Valletta, F., Vlachos, D., Schneider, T. R., Hellstern, V., De Marchis, G. M., & Dittrich, T. D. (2026). Dual Antiplatelet Therapy and Very Early Neurological Deterioration after Non-Cardioembolic Stroke According to Stroke Etiology. Cerebrovascular Diseases Extra. https://doi.org/10.1159/000552952

Vancouver

Pereppadan RS, Schärli S, Brülisauer S, Valletta F, Vlachos D, Schneider TR, et al. Dual Antiplatelet Therapy and Very Early Neurological Deterioration after Non-Cardioembolic Stroke According to Stroke Etiology. Cerebrovascular Diseases Extra. 2026. doi:10.1159/000552952

BibTeX
@article{Pereppadan2026,
  author = {Pereppadan, Rosa Sruthy and Schärli, Sabrina and Brülisauer, Shania and Valletta, Francesco and Vlachos, Dimitrios and Schneider, Thomas R and Hellstern, Victoria and De Marchis, Gian Marco and Dittrich, Tolga D},
  title = {Dual Antiplatelet Therapy and Very Early Neurological Deterioration after Non-Cardioembolic Stroke According to Stroke Etiology},
  journal = {Cerebrovascular Diseases Extra},
  year = {2026},
  doi = {10.1159/000552952}
}
Kostenlos starten →